Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges

Area of Science:

• Natural product chemistry
• Microbiology
• Pharmacology

Background:

• Tuberculosis (TB) remains a leading infectious cause of death globally, with rising drug-resistant strains necessitating new treatments.
• Mycobacterium tuberculosis (MTB) drug resistance is a growing concern, driving the search for novel therapeutic agents.
• Ursolic acid (UA), a plant-derived triterpene, has emerged as a potential candidate for anti-TB drug development.

Purpose of the Study:

• To review the therapeutic potential of Ursolic acid (UA) against Mycobacterium tuberculosis (MTB).
• To summarize in silico, in vitro, and in vivo evidence supporting UA's anti-TB activity.
• To discuss challenges and opportunities for developing UA as a novel anti-TB agent.

Main Methods:

• In silico studies identified UA's inhibitory mechanisms against MTB targets.
• In vitro studies evaluated UA's efficacy against drug-resistant strains and its synergy with existing drugs using assays like Microplate Alamar Blue Assay and Resazurin Assays.
• In vivo studies assessed UA's effectiveness in a murine model infected with multi-drug resistant MTB isolates.

Main Results:

• In silico analyses revealed UA's potential to inhibit key MTB enzymes, including enoyl acyl carrier protein reductase and FadA5.
• In vitro results demonstrated UA's effectiveness against drug-resistant TB and its synergistic activity with conventional anti-TB drugs.
• In vivo studies indicated UA's therapeutic promise in a relevant animal model.

Conclusions:

• Ursolic acid exhibits significant potential as a novel anti-TB agent, targeting multiple pathways and overcoming drug resistance.
• UA's synergistic effects with existing drugs offer a strategy to enhance treatment efficacy.
• Challenges related to UA's chemical complexity, availability, and intellectual property require resolution for successful clinical development.